Sironax is about halfway to its enrollment target in a Phase 2 trial of an oral NAMPT activator for adults with obesity.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results